Growth and Competition in China's GLP-1 Market

This document is a report detailing the dynamics of the glucagon-like peptide-1 (GLP-1) market in China, which is experiencing significant growth and competitive pressure. The report outlines projections indicating that the GLP-1 market in China could reach RMB 100 billion (approximately US$14 billion) by 2030, driven by increasing acceptance of GLP-1 therapies among healthcare providers and patients. It highlights the leading GLP-1 products, such as semaglutide and tirzepatide, which have achieved substantial sales figures globally. The report also discusses the expanding indications for GLP-1 therapies, including their potential applications in treating conditions like Alzheimer's disease and metabolic dysfunction-associated steatohepatitis (MASH). Additionally, it addresses the rising awareness of obesity as a chronic illness, influenced by governmental initiatives and the introduction of standardized treatment guidelines. The competitive landscape is evolving with numerous late-stage pipeline assets, indicating a shift towards differentiation in a crowded market. Furthermore, the imminent entry of generics is expected to challenge existing brands, intensifying the competitive environment.